Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study

[1]  D. Klonoff,et al.  The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record , 2021, Journal of diabetes science and technology.

[2]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[3]  C. Mathieu,et al.  Glucose control using fast‐acting insulin aspart in a real‐world setting: A 1‐year, two‐centre study in people with type 1 diabetes using continuous glucose monitoring , 2021, Diabetes, obesity & metabolism.

[4]  T. Danne,et al.  Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study , 2020, Diabetes technology & therapeutics.

[5]  Hai Li.  International consensus on time in range , 2019 .

[6]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[7]  J. Sturis,et al.  Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide , 2019, Pharmaceutical Research.

[8]  J. Buse,et al.  Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial , 2018, Diabetes, obesity & metabolism.

[9]  P. Kushner,et al.  Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis , 2018, Diabetes technology & therapeutics.

[10]  A. McCall,et al.  Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics , 2018, Diabetes Care.

[11]  C. Mathieu,et al.  Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial , 2018, Diabetes, obesity & metabolism.

[12]  R. Beck,et al.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading , 2017, Diabetes Care.

[13]  S. Heller,et al.  Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1) , 2017, Diabetes Care.

[14]  T. Pieber,et al.  A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes , 2017, Clinical Pharmacokinetics.

[15]  J. Lachin,et al.  Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up , 2016, Diabetes Care.

[16]  P. D. Home,et al.  Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? , 2015, Diabetes, obesity & metabolism.

[17]  J. Škrha,et al.  Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. , 2014, Diabetes technology & therapeutics.

[18]  Giovanni Sartore,et al.  Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes , 2013, Acta Diabetologica.

[19]  P. D. Home,et al.  The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences , 2012, Diabetes, obesity & metabolism.

[20]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[21]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[22]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[23]  K. Alberti,et al.  Basal and 24-h C-peptide and insulin secretion rate in normal man , 2005, Diabetologia.